Overview

• Sweden medical technology firm's Q2 net sales rose 34%, beating analyst expectations

• Organic growth reached 36% in local currencies, led by 53% rise in thoracic sales

• Q2 net profit and EPS improved year-over-year, supported by strong sales growth

Outlook

• XVIVO sees significant opportunities for growth across its portfolio and key markets

• Company expects increasing adoption of its technologies to drive future growth

Result Drivers

• THORACIC SALES - Strong growth in thoracic segment, with sales up 53% in local currencies, was the main driver of organic growth, per company

• ABDOMINAL SALES - Abdominal segment sales increased 26% in local currencies, contributing to overall growth

• SERVICES SALES DECLINE - Services sales decreased 25% in local currencies, partially offsetting product sales gains

Company press release: ID:nMFN4mQkS0

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Sales	Beat	SEK 239 mln	SEK 235.68 mln (4 Analysts)
Q2 EPS		SEK 0.52
Q2 Net Income		SEK 16.30 mln
Q2 EBIT		SEK 25 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK340.00, about 20.1% above its July 13 closing price of SEK283.00

• The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 56 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.